Sign Up Today and Learn More About Human Longevity Stock
Invest in or calculate the value of your shares in Human Longevity or other pre-IPO companies through EquityZen's platform.
About Human Longevity Stock
Founded
2013
Headquarters
San Diego, CA, US
Total Funding
300M
Industries
Science and Engineering, Health Care, Biotechnology
Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ™ Whole Genome and HLIQ Oncology.
Human Longevity Press Mentions
Stay in the know about the latest news on Human Longevity
Longevity clinics gather for a pivotal roundtable
longevity • Nov 12, 2024
Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging
news • Sep 23, 2024
Human Longevity Completes Upsized $39.8M Series B Financing
finsmes • Aug 22, 2024
Innovative Approaches to Improving Human Longevity
securities • Apr 25, 2024
Venture Capital Giants In The Billion-Dollar Quest For Longevity Breakthroughs
forbes • Apr 25, 2024
Investors in Human Longevity
Discover investors in Human Longevity stock and explore their portfolio companies
Human Longevity Management
Leadership team at Human Longevity
Co-Founder & CEO
J. Venter
Co-Founder & Vice Chairman
Robert Hariri
Join now and verify your accreditation status to gain access to:
- Human Longevity current valuation
- Human Longevity stock price
- Available deals in Human Longevity and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Human Longevity stock?
Accredited investors can buy pre-IPO stock in companies like Human Longevity through EquityZen funds. These investments are made available by existing Human Longevity shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Human Longevity stock?
Shareholders can sell their Human Longevity stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
